Current and future therapeutic options for the management of gout

Andrew Whelton

Research output: Contribution to journalArticle

Abstract

The incidence of gout and the clinical manifestation of hyperuricemia continue to rise. In addition to painful acute attacks, chronic gout can lead to the development of crystal arthropathy, tophi, and renal lithiasis, coincidental with declines in quality of life. As a greater appreciation for the associations between hyperuricemia, gout, and certain comorbidities, such as renal impairment and cardiovascular diseases, grows, so does the search for new therapeutic options to both alleviate the painful symptoms of acute gout attacks and reduce the underlying hyperuricemia. This manuscript reviews the pathophysiology of hyperuricemia and gout, and associated comorbidities, and then discusses traditional therapeutic options, newly available agents, and future targets for pharmacologic management.

Original languageEnglish (US)
Pages (from-to)402-417
Number of pages16
JournalAmerican Journal of Therapeutics
Volume17
Issue number4
DOIs
StatePublished - Jul 2010

Fingerprint

Gout
Hyperuricemia
Comorbidity
Kidney
Therapeutics
Lithiasis
Cardiovascular Diseases
Quality of Life
Incidence

Keywords

  • febuxostat
  • gout
  • hyperuricemia
  • uricase

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Current and future therapeutic options for the management of gout. / Whelton, Andrew.

In: American Journal of Therapeutics, Vol. 17, No. 4, 07.2010, p. 402-417.

Research output: Contribution to journalArticle

@article{68939d69d71d46aca878360aa72f9381,
title = "Current and future therapeutic options for the management of gout",
abstract = "The incidence of gout and the clinical manifestation of hyperuricemia continue to rise. In addition to painful acute attacks, chronic gout can lead to the development of crystal arthropathy, tophi, and renal lithiasis, coincidental with declines in quality of life. As a greater appreciation for the associations between hyperuricemia, gout, and certain comorbidities, such as renal impairment and cardiovascular diseases, grows, so does the search for new therapeutic options to both alleviate the painful symptoms of acute gout attacks and reduce the underlying hyperuricemia. This manuscript reviews the pathophysiology of hyperuricemia and gout, and associated comorbidities, and then discusses traditional therapeutic options, newly available agents, and future targets for pharmacologic management.",
keywords = "febuxostat, gout, hyperuricemia, uricase",
author = "Andrew Whelton",
year = "2010",
month = "7",
doi = "10.1097/MJT.0b013e3181df8ad2",
language = "English (US)",
volume = "17",
pages = "402--417",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Current and future therapeutic options for the management of gout

AU - Whelton, Andrew

PY - 2010/7

Y1 - 2010/7

N2 - The incidence of gout and the clinical manifestation of hyperuricemia continue to rise. In addition to painful acute attacks, chronic gout can lead to the development of crystal arthropathy, tophi, and renal lithiasis, coincidental with declines in quality of life. As a greater appreciation for the associations between hyperuricemia, gout, and certain comorbidities, such as renal impairment and cardiovascular diseases, grows, so does the search for new therapeutic options to both alleviate the painful symptoms of acute gout attacks and reduce the underlying hyperuricemia. This manuscript reviews the pathophysiology of hyperuricemia and gout, and associated comorbidities, and then discusses traditional therapeutic options, newly available agents, and future targets for pharmacologic management.

AB - The incidence of gout and the clinical manifestation of hyperuricemia continue to rise. In addition to painful acute attacks, chronic gout can lead to the development of crystal arthropathy, tophi, and renal lithiasis, coincidental with declines in quality of life. As a greater appreciation for the associations between hyperuricemia, gout, and certain comorbidities, such as renal impairment and cardiovascular diseases, grows, so does the search for new therapeutic options to both alleviate the painful symptoms of acute gout attacks and reduce the underlying hyperuricemia. This manuscript reviews the pathophysiology of hyperuricemia and gout, and associated comorbidities, and then discusses traditional therapeutic options, newly available agents, and future targets for pharmacologic management.

KW - febuxostat

KW - gout

KW - hyperuricemia

KW - uricase

UR - http://www.scopus.com/inward/record.url?scp=77955012787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955012787&partnerID=8YFLogxK

U2 - 10.1097/MJT.0b013e3181df8ad2

DO - 10.1097/MJT.0b013e3181df8ad2

M3 - Article

C2 - 20562597

AN - SCOPUS:77955012787

VL - 17

SP - 402

EP - 417

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 4

ER -